middle.news

How Will Opthea Rebound After Dropping Wet AMD Drug and Settling Funding Deal?

4:45am on Saturday 30th of August, 2025 AEST Healthcare
Read Story

How Will Opthea Rebound After Dropping Wet AMD Drug and Settling Funding Deal?

4:45am on Saturday 30th of August, 2025 AEST
Key Points
  • Revenue up 57.9% to US$5.56 million
  • Net loss narrowed 26% to US$162.8 million
  • Discontinued sozinibercept development after negative Phase III results
  • Settled Development Funding Agreement with US$20 million payment and 9.99% equity issuance
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Opthea (ASX:OPT)
OPEN ARTICLE